ESPR
Esperion Therapeutics, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $342.7K.
- InstitutionsBEARISH
Q3 2026: 0 added (0 new), 9 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.007 → −$0.070 over 90 days. 1 up, 0 down in 30 days.
- Short sellersCOVERING
Short interest −16.0% to 17.40M shares. 1.7 days to cover, ≈6.8% of shares.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| UBS Group AG | EXIT | $0.00 |
| STATE STREET CORP | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | DOUBLED | $32.8M |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | $14.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2026| Date | Firm | Rating |
|---|---|---|
| May 4, 2026 | Needham DOWNGRADE | Hold |
| May 1, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Mar 13, 2026 | Citizens MAINTAIN | Market Outperform |
| Mar 3, 2026 | Needham MAINTAIN | Buy |
| Nov 25, 2025 | Piper Sandler INITIATE | Overweight |
| Sep 19, 2025 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Koenig Sheldon L. President and CEO Jul 13, 2026 | TO ISSUER | 647,460 sh |
Halladay Benjamin Chief Financial Officer Jul 13, 2026 | TO ISSUER | 200,000 sh |
Hoffman Robert E. Director Jul 13, 2026 | TO ISSUER | 85,153 sh |
Hoffman Robert E. Director Jul 13, 2026 | TO ISSUER | 40,000 sh |
Hoffman Robert E. Director Jul 13, 2026 | TO ISSUER | 7,040 sh |
CARROLL J MARTIN Director Jul 13, 2026 | TO ISSUER | 177,523 sh |
CARROLL J MARTIN Director Jul 13, 2026 | TO ISSUER | 21,000 sh |
Looker Benjamin Chief Legal Officer Jul 13, 2026 | TO ISSUER | 667,524 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next FY | $0.26 | $0.09–$0.49 | -11.8% | $439.0M |
| Current Q | -$0.07 | -$0.07–-$0.07 | +0.0% | $76.6M |
| Next Q | -$0.04 | -$0.04–-$0.04 | +0.0% | $85.5M |
| Current FY | -$0.21 | -$0.21–-$0.21 | +0.0% | $337.6M |
Short side
FINRA· Jun 30, 2026| Jul 10, 2026 | Deletion | Resumed |
SecBot reports
17 filings · 4 press releases · 8 bullish · 4 bearish · 1 mixed · 4 neutral- BEARISH SC 13G/ANov 10, 2026
Goldman Sachs Group Inc. filed an amendment to its Schedule 13G for Esperion Therapeutics…
Monitor for additional institutional selling or further 13G amendments from other holders. The exit by a top holder may signal reduced institutional confidence ahead of upcoming catalysts or earnings.
- BULLISH COURT-RULINGSep 3, 2026
Esperion Therapeutics won a favorable claim construction ruling in the Nexletol/Nexlizet ANDA…
The favorable claim construction improves Esperion's leverage in the ANDA litigation, potentially increasing the likelihood of CVR payments. Monitor for subsequent infringement/validity rulings and…
- BEARISH INST-CLUSTERAug 13, 2026
Esperion Therapeutics (ESPR) saw a mixed institutional cluster in 2026-Q2: 6 buyers (net +$5.0M)…
The dominant signal is the near-exit of Wasatch Advisors, a significant active holder, which sold ~13.8M shares. Monitor for further institutional distribution in upcoming 13F filings and any…
- NEUTRAL 15-12GJul 23, 2026
Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g)…
The deregistration is the final step in the going-private transaction. No further public trading or SEC filings are expected. Shareholders who tendered shares in the merger have already received the…
All ESPR filing & press-release reports (21)
- SC 13G/A reportNov 10, 2026
- COURT-RULING reportSep 3, 2026
- INST-CLUSTER reportAug 13, 2026
- 15-12G reportJul 23, 2026
- EFFECT reportJul 16, 2026
- EFFECT reportJul 16, 2026
- 25-NSE reportJul 13, 2026
- 8-K reportJul 13, 2026
- DEFA14A reportJun 16, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 9, 2026
- DEFM14A reportJun 8, 2026
- 8-K reportJun 1, 2026
- PREM14A reportMay 29, 2026
- PRESS-RELEASE reportMay 26, 2026
- DEFA14A reportMay 1, 2026
- PRESS-RELEASE reportMay 1, 2026
- PRESS-RELEASE reportApr 23, 2026
- CLUSTER reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026
- PRESS-RELEASE reportMar 3, 2026